Article Text
Therapeutics/Prevention
Randomised controlled trial
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection
Statistics from Altmetric.com
Footnotes
Competing interests AD has received research funding from Clorox, 3M and Steris.
Provenance and peer review Commissioned; internally peer reviewed.